세계의 아보넥스(Avonex) 시장 보고서(2025년) : 역학, 파이프라인 분석, 시장 인사이트 및 예측

Avonex, a brand of interferon beta-1a, is primarily used to treat relapsing forms of multiple sclerosis (MS). It is effective in reducing relapse frequency and slowing the progression of physical disability associated with MS. As an immunomodulator, Avonex works by modifying the immune system's activity, reducing inflammation, and limiting nervous system damage caused by the disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of avonex are prefilled syringes and powder forms. Prefilled syringes are single-dose containers that come ready for injection, pre-filled with the medication and equipped with a needle, offering convenience for various medical treatments. The clinical indications for Avonex include relapsing forms of multiple sclerosis (RMS), clinically isolated syndrome (CIS), relapse rate reduction in MS, slowing disability progression, long-term disease management in MS, and early-stage MS treatment. It is distributed through multiple channels such as wholesalers, retail pharmacies, and direct-to-patient (DTP) sales, and is used in settings like hospitals, drug stores, and others.

The avonex market research report is one of a series of new reports from The Business Research Company that provides avonex market statistics, including avonex industry global market size, regional shares, competitors with a avonex market share, detailed avonex market segments, market trends and opportunities, and any further data you may need to thrive in the avonex industry. This avonex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The avonex market size is expected to see strong growth in the next few years. It will grow to $2,439.2 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to rise in multiple sclerosis (MS) prevalence, increasing preference for oral medications, rising patient support expectations, increasing clinical evidence supporting efficacy, increasing market share of injectable alternatives. Major trends in the forecast period include advanced data analytics, demand for biological indicators, utilization of 3D bioprinting, integration of immunomodulatory technology, use of nanotechnology.

The increasing prevalence of multiple sclerosis (MS) is expected to drive the growth of the avonex market. MS is a chronic autoimmune disease where the immune system attacks the protective myelin sheath surrounding nerve fibers in the central nervous system, causing disruptions in brain-body communication. The rise in MS cases can be attributed to improved diagnostic capabilities, environmental factors such as vitamin D deficiency, genetic predisposition, and changes in lifestyle and migration patterns. Avonex is critical in managing MS by reducing inflammation, decreasing relapse frequency, and slowing physical disability progression through immune system modulation. For example, a report published by the Multiple Sclerosis Trust in May 2024 revealed a nearly 13% increase in the number of people living with MS in the UK, with a 15% rise in England, 10% in Scotland, 9% in Northern Ireland, and 8% in Wales. This growing prevalence underscores the rising demand for avonex in managing MS, fueling market growth.

A key trend in the avonex market is the development of strategic partnerships aimed at enhancing treatment options, patient outcomes, and chronic disease management. Strategic partnerships allow organizations to combine strengths, resources, and expertise to achieve mutual goals and improve competitive advantage. For instance, in June 2022, Biogen Inc., the US-based manufacturer of Avonex (interferon beta-1a), collaborated with Happify Health to create an AI-powered digital solution. This platform enhances patient education and engagement for individuals living with MS, offering tools to manage care, access expert consultations, and explore treatment options while fostering a supportive community.

In November 2024, Vanguard Group Inc., a US-based investment firm, acquired shares in Biogen Inc. for an undisclosed amount. This acquisition reflects Vanguard's strategy to diversify its investment portfolio and support companies with strong growth potential and innovative product pipelines, further strengthening Biogen's position in the Avonex market.

Key player operating in the avonex market is Biogen Inc

North America was the largest region in the avonex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in avonex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the avonex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The avonex market consists of sales of monoclonal antibodies, spinal muscular atrophy medications, biosimilars and immunomodulators. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Avonex Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on avonex market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for avonex ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The avonex market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Prefilled Syringe; Powder Form
• 2) Clinical Indication: Relapsing Forms Of Multiple Sclerosis (RMS); Clinically Isolated Syndrome (CIS); Relapse Rate Reduction In MS; Slowing Disability Progression; Long-term Disease Management In MS; Early-Stage MS Treatment
• 2) By Distribution Channel: Wholesalers; Retail Pharmacies; Direct-To-Patient (Dtp) Sales
• 3) By Application: Hospital; Drugs Store; Other Applications
• Companies Mentioned: Biogen Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Avonex Market Characteristics

3. Avonex Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Avonex Market Trends And Strategies

5. Avonex Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Avonex Growth Analysis And Strategic Analysis Framework

• 6.1. Global Avonex PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Avonex Market Growth Rate Analysis
• 6.4. Global Avonex Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 6.5. Global Avonex Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 6.6. Global Avonex Total Addressable Market (TAM)

7. Global Avonex Market Pricing Analysis & Forecasts

8. Avonex Market Segmentation

• 8.1. Global Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prefilled Syringe
• Powder Form
• 8.2. Global Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Relapsing Forms Of Multiple Sclerosis (RMS)
• Clinically Isolated Syndrome (CIS)
• Relapse Rate Reduction In MS
• Slowing Disability Progression
• Long-term Disease Management in MS
• Early-Stage MS Treatment
• 8.3. Global Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wholesalers
• Retail Pharmacies
• Direct-To-Patient (Dtp) Sales
• 8.4. Global Avonex Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Drug Stores
• Other Applications

9. Global Avonex Market Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Avonex Market Regional And Country Analysis

• 10.1. Global Avonex Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. Global Avonex Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Avonex Market

• 11.1. Asia-Pacific Avonex Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Asia-Pacific Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Asia-Pacific Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Avonex Market

• 12.1. China Avonex Market Overview
• 12.2. China Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.3. China Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 12.4. China Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Avonex Market

• 13.1. India Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. India Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. India Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Avonex Market

• 14.1. Japan Avonex Market Overview
• 14.2. Japan Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. Japan Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. Japan Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Avonex Market

• 15.1. Australia Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.2. Australia Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Australia Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Avonex Market

• 16.1. South Korea Avonex Market Overview
• 16.2. South Korea Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. South Korea Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.4. South Korea Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Avonex Market

• 17.1. Western Europe Avonex Market Overview
• 17.2. Western Europe Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Western Europe Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.4. Western Europe Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Avonex Market

• 18.1. UK Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. UK Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. UK Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Avonex Market

• 19.1. Germany Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Germany Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Germany Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Avonex Market

• 20.1. France Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. France Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. France Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Avonex Market

• 21.1. Eastern Europe Avonex Market Overview
• 21.2. Eastern Europe Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Avonex Market

• 22.1. North America Avonex Market Overview
• 22.2. North America Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. North America Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.4. North America Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Avonex Market

• 23.1. USA Avonex Market Overview
• 23.2. USA Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. USA Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. USA Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Avonex Market

• 24.1. Canada Avonex Market Overview
• 24.2. Canada Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. Canada Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. Canada Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Avonex Market

• 25.1. South America Avonex Market Overview
• 25.2. South America Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. South America Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. South America Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Avonex Market

• 26.1. Middle East Avonex Market Overview
• 26.2. Middle East Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. Middle East Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. Middle East Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Avonex Market

• 27.1. Africa Avonex Market Overview
• 27.2. Africa Avonex Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Africa Avonex Market, Segmentation By Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.4. Africa Avonex Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Avonex Market Competitive Landscape And Company Profiles

• 28.1. Avonex Market Competitive Landscape
• 28.2. Avonex Market Company Profiles
  • 28.2.1. Biogen Inc Overview, Products and Services, Strategy and Financial Analysis

29. Global Avonex Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Avonex Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Avonex Market

32. Recent Developments In The Avonex Market

33. Avonex Market High Potential Countries, Segments and Strategies

• 33.1 Avonex Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Avonex Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Avonex Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer